Download a Sample Report Now to know more about the report coverage.
The market is driven by rising chronic diseases. In addition, the spread of the COVID-19 infection is anticipated to boost the growth of the advanced drug delivery systems market.
The prevalence of various chronic diseases has increased steadily across the world over the years. For instance, the number of patients with CVDs nearly doubled from 271 million in 1990 to 523 million in 2019. The increasing prevalence of such diseases can be attributed to the adoption of unhealthy and sedentary lifestyles, increasing geriatric population, excessive consumption of saturated trans-fat food, tobacco consumption, obesity, physical inactivity, and family history of CVDs. According to a study, in 2019, about 28.2 million adults in the US were diagnosed with heart diseases. Also, every year, about 805,000 cases of deaths are recorded in the US caused by various heart diseases. The growing prevalence of various chronic diseases is increasing the demand for new drugs. This, in turn, is driving the growth of the market in focus.
Learn about other factors impacting the market growth. Request a Sample Report Now
Major Vendors in Advanced Drug Delivery Systems Market:
The global advanced drug delivery systems market is fragmented due to the presence of several regional and international players. Vendors are deploying various growth strategies such as new product launches, investments in R&D, and M&As to remain competitive in the market. Technavio identifies the following as the dominant players in the market.
- 3M Co.: The company offers drug delivery systems such as Liner Fluoropolymer Coated Polyester Film and Polyester Backing Film Laminate.
- Alkermes Public Co. Ltd.: The company offers drug development efforts that are focused on two scientific research platforms, namely Synaptic Dysfunction and Immune Modulation in Oncology.
- Antares Pharma Inc.: The company offers drug delivery devices such as Vibex Auto-Injector and Vibex Variable Dose. These products can be tailor-made as per patient and therapeutic needs.
- Baxter International Inc.: The company offers versatile, tailored solutions such as advanced drug delivery systems to help achieve commercialization objectives.
- Becton Dickinson and Co.: The company offers needle technologies, prefillable syringes, safety and shielding systems, and self-injection systems.
Gain access to more vendor profiles and their key offerings by purchasing our full report.
View Our Sample Report Before Purchasing
Advanced Drug Delivery Systems Market: Segmentation Analysis
The 120-pages report segments the global advanced drug delivery systems market by type (oral, injection and inhalation, transdermal, carrier-based, and others) and geography (North America, Europe, Asia, and ROW).
Advanced Drug Delivery Systems Market: Type Outlook (Revenue, USD Billion, 2021-2026)
- Oral - size and forecast 2021-2026
- Injection and inhalation - size and forecast 2021-2026
- Transdermal - size and forecast 2021-2026
- Carrier-based - size and forecast 2021-2026
- Others - size and forecast 2021-2026
The oral segment generated maximum revenue in the market in 2021. The market growth in the segment will be significant over the forecast period.
Advanced Drug Delivery Systems Market: Geography Outlook (Revenue, USD Billion, 2021-2026)
- North America - size and forecast 2021-2026
- Europe - size and forecast 2021-2026
- Asia - size and forecast 2021-2026
- ROW - size and forecast 2021-2026
North America will offer maximum growth opportunities for market players. The high adoption of improved drug delivery solutions and the availability of advanced treatment options are driving the growth of the regional market. The US is the key market for advanced drug delivery systems in North America.
Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.
Request Our Sample Report
Related Reports:
Smart Pills Drug Delivery Market by Application and Geography - Forecast and Analysis 2022-2026
New Drug Delivery Systems Market by Route of Administration and Geography - Forecast and Analysis 2022-2026
Advanced Drug Delivery Systems Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Decelerate at a CAGR of 7.41% |
Market growth 2022-2026 |
USD 91.79 billion |
Market structure |
Fragmented |
YoY growth (%) |
9.97 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 44% |
Key consumer countries |
US, UK, China, Germany, and France |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
3M Co., Alkermes Public Co. Ltd., Antares Pharma Inc., Baxter International Inc., Becton Dickinson and Co., Endo International Plc, NanoPass Technologies Ltd., Nektar Therapeutics, Perrigo Co. Plc, and Teva Pharmaceutical Industries Ltd. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding 1
Exhibit 02: Key Finding 2
Exhibit 03: Key Finding 3
Exhibit 04: Key Finding 5
Exhibit 05: Key Finding 6
Exhibit 06: Key Finding 7
Exhibit 07: Key Finding 8
2. Market Landscape
2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market Characteristics
2.2 Value chain analysis
Exhibit 10: Value chain analysis: Life Sciences Tools and Services
2.2.1 Research and development
2.2.2 Inputs
2.2.3 Production
2.2.4 Distribution
2.2.5 Marketing and sales
2.2.6 Post-sales and services
2.2.7 Industry innovations
3. Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021 - 2026
3.4.1 Estimating growth rates for emerging and high-growth markets
3.4.2 Estimating growth rates for mature markets
Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ billion)
Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 15: Five forces analysis 2021 & 2026
4.2 Bargaining power of buyers
Exhibit 16: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 17: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 18: Threat of new entrants
4.5 Threat of substitutes
Exhibit 19: Threat of substitutes
4.6 Threat of rivalry
Exhibit 20: Threat of rivalry
4.7 Market condition
Exhibit 21: Market condition - Five forces 2021
5. Market Segmentation by Type
5.1 Market segments
The segments covered in this chapter are:
- Oral
- Injection and inhalation
- Transdermal
- Carrier-based
- Others
Exhibit 22: Type - Market share 2021-2026 (%)
5.2 Comparison by Type
Exhibit 23: Comparison by Type
5.3 Oral - Market size and forecast 2021-2026
Exhibit 24: Oral - Market size and forecast 2021-2026 ($ billion)
Exhibit 25: Oral - Year-over-year growth 2021-2026 (%)
5.4 Injection and inhalation - Market size and forecast 2021-2026
Exhibit 26: Injection and inhalation - Market size and forecast 2021-2026 ($ billion)
Exhibit 27: Injection and inhalation - Year-over-year growth 2021-2026 (%)
5.5 Transdermal - Market size and forecast 2021-2026
Exhibit 28: Transdermal - Market size and forecast 2021-2026 ($ billion)
Exhibit 29: Transdermal - Year-over-year growth 2021-2026 (%)
5.6 Carrier-based - Market size and forecast 2021-2026
Exhibit 30: Carrier-based - Market size and forecast 2021-2026 ($ billion)
Exhibit 31: Carrier-based - Year-over-year growth 2021-2026 (%)
5.7 Others - Market size and forecast 2021-2026
Exhibit 32: Others - Market size and forecast 2021-2026 ($ billion)
Exhibit 33: Others - Year-over-year growth 2021-2026 (%)
5.8 Market opportunity by Type
Exhibit 34: Market opportunity by Type
6. Customer landscape
6.1 Overview
Exhibit 35: Customer landscape
7. Geographic Landscape
7.1 Geographic segmentation
The regions covered in the report are:
- North America
- Europe
- Asia
- ROW
Exhibit 36: Market share by geography 2021-2026 (%)
7.2 Geographic comparison
Exhibit 37: Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 38: North America - Market size and forecast 2021-2026 ($ billion)
Exhibit 39: North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 40: Europe - Market size and forecast 2021-2026 ($ billion)
Exhibit 41: Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 42: Asia - Market size and forecast 2021-2026 ($ billion)
Exhibit 43: Asia - Year-over-year growth 2021-2026 (%)
7.6 ROW - Market size and forecast 2021-2026
Exhibit 44: ROW - Market size and forecast 2021-2026 ($ billion)
Exhibit 45: ROW - Year-over-year growth 2021-2026 (%)
7.7 Key leading countries
Exhibit 46: Key leading countries
7.9 Market opportunity by geography
Exhibit 47: Market opportunity by geography ($ billion)
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Rising chronic diseases
8.1.2 Rising investment in research and development of drug delivery
8.1.3 Rising healthcare expenditure globally
8.2 Market challenges
8.2.1 Presence of stringent regulations
8.2.2 Poor healthcare infrastructure in underdeveloped or developing countries
8.2.3 Biocompatibility and acceptability with human body
Exhibit 48: Impact of drivers and challenges
8.3 Market trends
8.3.1 Covid-19 pandemic to create multiple opportunities in the market
8.3.2 Introduction of targeted drug delivery system
8.3.3 Reduced side effects
9. Vendor Landscape
9.1 Overview
Exhibit 49: Vendor landscape
9.2 Landscape disruption
Exhibit 50: Landscape disruption
Exhibit 51: Industry risks
10. Vendor Analysis
10.1 Vendors covered
Exhibit 52: Vendors covered
10.2 Market positioning of vendors
Exhibit 53: Market positioning of vendors
10.3 3M Co.
Exhibit 54: 3M Co. - Overview
Exhibit 55: 3M Co. - Business segments
Exhibit 56: 3M Co. - Key offerings
Exhibit 57: 3M Co. - Segment focus
10.4 Alkermes Public Co. Ltd.
Exhibit 58: Alkermes Public Co. Ltd. - Overview
Exhibit 59: Alkermes Public Co. Ltd. - Business segments
Exhibit 60: Alkermes Public Co. Ltd. - Key news
Exhibit 61: Alkermes Public Co. Ltd. - Key offerings
10.5 Antares Pharma Inc.
Exhibit 62: Antares Pharma Inc. - Overview
Exhibit 63: Antares Pharma Inc. - Business segments
Exhibit 64: Antares Pharma Inc. - Key news
Exhibit 65: Antares Pharma Inc. - Key offerings
10.6 Baxter International Inc.
Exhibit 66: Baxter International Inc. - Overview
Exhibit 67: Baxter International Inc. - Business segments
Exhibit 68: Baxter International Inc. - Key offerings
Exhibit 69: Baxter International Inc. - Segment focus
10.7 Becton Dickinson and Co.
Exhibit 70: Becton Dickinson and Co. - Overview
Exhibit 71: Becton Dickinson and Co. - Business segments
Exhibit 72: Becton Dickinson and Co. - Key offerings
Exhibit 73: Becton Dickinson and Co. - Segment focus
10.8 Endo International Plc
Exhibit 74: Endo International Plc - Overview
Exhibit 75: Endo International Plc - Business segments
Exhibit 76: Endo International Plc. - Key news
Exhibit 77: Endo International Plc - Key offerings
Exhibit 78: Endo International Plc - Segment focus
10.9 NanoPass Technologies Ltd.
Exhibit 79: NanoPass Technologies Ltd. - Overview
Exhibit 80: NanoPass Technologies Ltd. - Product and service
Exhibit 81: NanoPass Technologies Ltd. - Key offerings
10.10 Nektar Therapeutics
Exhibit 82: Nektar Therapeutics - Overview
Exhibit 83: Nektar Therapeutics - Product and service
Exhibit 84: Nektar Therapeutics - Key offerings
10.11 Perrigo Co. Plc
Exhibit 85: Perrigo Co. Plc - Overview
Exhibit 86: Perrigo Co. Plc - Business segments
Exhibit 87: Perrigo Co. Plc - Key offerings
Exhibit 88: Perrigo Co. Plc - Segment focus
10.12 Teva Pharmaceutical Industries Ltd.
Exhibit 89: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 90: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 91: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 92: Teva Pharmaceutical Industries Ltd. - Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 ????Market definition
11.1.2 Objective
11.1.3 Notes and caveats
11.2 Currency conversion rates for US$
Exhibit 93: Currency conversion rates for US$
11.3 Research Methodology
Exhibit 94: Research Methodology
Exhibit 95: Validation techniques employed for market sizing
Exhibit 96: Information sources
11.4 List of abbreviations
Exhibit 97: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article